Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Antivirals Stories

2013-06-27 08:29:42

EXTON, Pa., June 27, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced updated data from the two ongoing, Phase 2 dose ranging studies investigating maribavir for both first line treatment of cytomegalovirus (CMV) viremia and treatment of resistant/refractory CMV. ViroPharma is currently conducting two Phase 2 dose ranging studies of oral maribavir at one of three doses (400mg, 800mg or 1200mg BID) in transplant recipients. The first is a randomized,...

2013-06-13 16:25:56

RnR Market Research adds new HCV Drugs market research reports by GlobalData for US, Japan, Brazil China, France, Germany, Italy, Spain and the UK with an in-depth analysis on the companies in these countries. DALLAS, June 13, 2013 /PRNewswire-iReach/ -- RnRMarketResearch.com now offers new market research reports on the Hepatitis C Virus drug industry for US, Japan, Brazil China, France, Germany, Italy, Spain and the UK with an in-depth analysis on the companies in these countries....

2013-06-11 04:22:21

EXTON, Pa., June 11, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral (CMV) disease in patients with impaired cell mediated immunity. The "Orphan Medicinal Product Designation" is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases identified as "life-threatening or chronically...

2013-06-06 23:21:35

In its survey for the month of June, polyDNA found that many people had questions and were confused about what it means to be ℠cured´ of a herpes or HPV infection. polyDNA answered these questions in a new section on its website. Rochester, NY (PRWEB) June 06, 2013 polyDNA´s monthly survey, taken during June 2013, showed that many people are confused about the meaning of the term ℠cure´ as in ℠herpes cure´ or ℠HPV cure´. Because of this...

2013-06-04 12:26:04

Expansion of Therapies Offering Benefits Over Current Standard of Care Will Drive Growth Despite Price Controls in Market, According to a New Report from Decision Resources BURLINGTON, Mass., June 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the hepatitis C virus (HCV) market in Turkey will more than triple, reaching $275 million in 2017. The Emerging...

2013-05-21 08:29:31

ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when...

2013-05-15 11:48:06

Animals, insects, and plants use a variety of sensing mechanisms to detect invading pathogens such as viruses. One complex and effective antiviral defense system they share is based on recognition of double-stranded RNA (dsRNA), often produced when a virus invades a host cell. New information leading to a clearer understanding of the mechanisms underlying viral dsRNA sensing is presented in a comprehensive Review article published in Journal of Interferon & Cytokine Research, a...

2013-05-13 08:27:15

However, Recent Changes in Brazil and Argentina are Expected to Drive a Shift in Treatment of HCV Genotype 1 Infections, According to a New Report From Decision Resources BURLINGTON, Mass., May 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of hepatitis C virus (HCV) patients in Brazil, Mexico and Argentina rely entirely on government-sponsored medical programs to...

2013-05-02 16:30:47

NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Association for the Study of the Liver (EASL). A pre-recorded webcast featuring management from Janssen will provide an overview...

2013-05-02 08:32:04

An All-Oral/Interferon-Free Regimen is One of the Great Unmet Needs in Treatment-Naive HCV, According to a New Report from Decision Resources BURLINGTON, Mass., May 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of genotype-1 hepatitis C virus (HCV) patients achieving a sustained virological...